Skip to main content
SpringerLink
Log in

PET and SPECT in Psychiatric Complications of Parkinson’s Disease

  • Chapter
  • First Online:
PET and SPECT in Psychiatry

  • 758 Accesses

Abstract

The psychiatric complications of Parkinson’s disease (PD) are a source of additional disability and greatly reduce the quality of life of both the patients and the caregivers. Depression, psychosis, impulse control disorders, and other comorbid psychiatric disorders in PD may result from both intrinsic disease-related and iatrogenic treatment-related factors. Functional neuroimaging with PET and SPECT, with tracers for monoamine transmitters, glucose metabolism, and cerebral blood flow, has been used to reveal neuropathophysiological processes underlying specific psychiatric complications of PD. This chapter covers the current knowledge concerning brain PET and SPECT imaging in the psychiatric complications of PD, with a particular focus on the dopaminergic system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BDI:

Beck depression inventory

CNS:

Central nervous system

DAT:

Dopamine transporter

ECD:

[99mTc]ethyl-cysteinate-dimer-bicisate

FDOPA:

6-[18F]fluoro-L-DOPA

MADRS:

Montgomery-Åsberg Depression Rating Scale

PD:

Parkinson’s disease

PET:

Positron-emission tomography

rCBF:

Regional cerebral blood flow

ROI:

Region of interest

SERT:

Serotonin transporter

SPECT:

Single-photon emission computed tomography

SPM:

Statistical parametric mapping

References

  • Abe N, Fujii T, Hirayama K, Takeda A, Hosokai Y, Ishioka T, Nishio Y, Suzuki K, Itoyama Y, Takahashi S, Fukuda H, Mori E (2009) Do parkinsonian patients have trouble telling lies? The neurobiological basis of deceptive behaviour. Brain 132:1386–1395

    PubMed  PubMed Central  Google Scholar 

  • Ambermoon P, Carter A, Hall WD, Dissanayaka NN, O’Sullivan JD (2011) Impulse control disorders in patients with Parkinson’s disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction 106:283–293

    PubMed  Google Scholar 

  • Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL (1997) Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 12:33–38

    CAS  PubMed  Google Scholar 

  • Arabia G, Grossardt BR, Colligan RC, Bower JH, Maraganore DM, Ahlskog JE, Geda YE, Rocca WA (2010) Novelty seeking and introversion do not predict the long-term risk of Parkinson disease. Neurology 75:349–357

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH (2010) Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 67:416–421

    PubMed  Google Scholar 

  • Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, Tremblay L, Sgambato-Faure V, Broussolle E, Thobois S (2012) Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson’s disease. Mov Disord 27:84–89

    CAS  PubMed  Google Scholar 

  • Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, Houle S, Wilson AA, Meyer JH, Kish SJ (2008) Elevated serotonin transporter binding in depressed patients with Parkinson’s disease: a preliminary PET study with [11C]DASB. Mov Disord 23:1776–1780

    PubMed  Google Scholar 

  • Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y, Wilson AA, Kapur S, Kish SJ (2009) Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson’s disease. Brain 132:1366–1375

    PubMed  Google Scholar 

  • Broussolle E, Dentresangle C, Landais P, Garcia-Larrea L, Pollak P, Croisile B, Hibert O, Bonnefoi F, Galy G, Froment JC, Comar D (1999) The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease. J Neurol Sci 166:141–151

    CAS  PubMed  Google Scholar 

  • Ceravolo R, Frosini D, Rossi C, Bonuccelli U (2009) Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 15(Suppl 4):S111–S115

    PubMed  Google Scholar 

  • Cho SS, Strafella AP, Duff-Canning S, Zurowski M, Vijverman AC, Bruno V, Aquino CC, Criaud M, Rusjan PM, Houle S, Fox SH (2017) The relationship between serotonin-2A receptor and cognitive functions in nondemented Parkinson’s disease patients with visual hallucinations. Mov Disord Clin Pract 4:698–709

    PubMed  PubMed Central  Google Scholar 

  • Chung SJ, Lee JJ, Ham JH, Lee PH, Sohn YH (2016) Apathy and striatal dopamine defects in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord 23:62–65

    PubMed  Google Scholar 

  • Cilia R, Siri C, Marotta G, Isaias IU, De Gaspari D, Canesi M, Pezzoli G, Antonini A (2008) Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 65:1604–1611

    PubMed  Google Scholar 

  • Cilia R, Ko JH, Cho SS, van Eimeren T, Marotta G, Pellecchia G, Pezzoli G, Antonini A, Strafella AP (2010) Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis 39:98–104

    CAS  PubMed  Google Scholar 

  • Cilia R, Cho SS, van Eimeren T, Marotta G, Siri C, Ko JH, Pellecchia G, Pezzoli G, Antonini A, Strafella AP (2011) Pathological gambling in patients with Parkinson’s disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord 26:225–233

    PubMed  Google Scholar 

  • Cropley VL, Fujita M, Bara-Jimenez W, Brown AK, Zhang XY, Sangare J, Herscovitch P, Pike VW, Hallett M, Nathan PJ, Innis RB (2008) Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 163:171–182

    CAS  PubMed  Google Scholar 

  • Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64:327–337

    CAS  PubMed  Google Scholar 

  • van Eimeren T, Pellecchia G, Cilia R, Ballanger B, Steeves TD, Houle S, Miyasaki JM, Zurowski M, Lang AE, Strafella AP (2010) Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 75:1711–1716

    PubMed  PubMed Central  Google Scholar 

  • Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, Brooks DJ, Lees AJ, Piccini P (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59:852–858

    CAS  PubMed  Google Scholar 

  • Even C, Weintraub D (2012) Is depression in Parkinson’s disease (PD) a specific entity? J Affect Disord 139:103–112

    PubMed  Google Scholar 

  • Felicio AC, Moriyama TS, Godeiro-Junior C, Shih MC, Hoexter MQ, Borges V, Silva SM, Amaro-Junior E, Andrade LA, Ferraz HB, Bressan RA (2010) Higher dopamine transporter density in Parkinson’s disease patients with depression. Psychopharmacology 211:27–31

    CAS  PubMed  Google Scholar 

  • Fénelon G, Alves G (2010) Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 289:12–17

    PubMed  Google Scholar 

  • Fregni F, Ono CR, Santos CM, Bermpohl F, Buchpiguel C, Barbosa ER, Marcolin MA, Pascual-Leone A, Valente KD (2006) Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. Neurology 66:1629–1637

    CAS  PubMed  Google Scholar 

  • Gallagher DA, O’Sullivan SS, Evans AH, Lees AJ, Schrag A (2007) Pathological gambling in Parkinson’s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 22:1757–1763

    PubMed  Google Scholar 

  • Galts CPC, Betto LEB, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, Thacker JS, Gil-Mohapel J (2019) Depression in neurodegenerative diseases: common mechanisms and treatment options. Neurosci Biobehav Rev 102:56–84

    PubMed  Google Scholar 

  • Georgiev D, Danieli A, Ocepek L, Novak D, Zupancic-Kriznar N, Trost M, Pirtosek Z (2010) Othello syndrome in patients with Parkinson’s disease. Psychiatr Danub 22:94–98

    PubMed  Google Scholar 

  • Grosset KA, Macphee G, Pal G, Stewart D, Watt A, Davie J, Grosset DG (2006) Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 21:2206–2208

    PubMed  Google Scholar 

  • Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, Isaias IU, Schwarz J, Sabri O (2009) Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging 36:428–435

    CAS  PubMed  Google Scholar 

  • Hirvonen J, Aalto S, Lumme V, Någren K, Kajander J, Vilkman H, Hagelberg N, Oikonen V, Hietala J (2003) Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride. Nucl Med Commun 24:1207–1214

    CAS  PubMed  Google Scholar 

  • Holden C (2010) Psychiatry. Behavioral addictions debut in proposed DSM-V. Science 327:935

    CAS  PubMed  Google Scholar 

  • Imamura K, Okayasu N, Nagatsu T (2011) The relationship between depression and regional cerebral blood flow in Parkinson’s disease and the effect of selegiline treatment. Acta Neurol Scand 124:28–39

    CAS  PubMed  Google Scholar 

  • Ishihara L, Brayne C (2006) What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov Disord 21:1066–1072

    PubMed  Google Scholar 

  • Ishii T, Sawamoto N, Tabu H, Kawashima H, Okada T, Togashi K, Takahashi R, Fukuyama H (2016) Altered striatal circuits underlie characteristic personality traits in Parkinson’s disease. J Neurol 263:1828–1839

    PubMed  Google Scholar 

  • Jaakkola E, Joutsa J, Mäkinen E, Johansson J, Kaasinen V (2017) Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson’s disease. Eur J Neurol 24:1341–1347

    CAS  PubMed  Google Scholar 

  • Joutsa J, Johansson J, Niemelä S, Ollikainen A, Hirvonen MM, Piepponen P, Arponen E, Alho H, Voon V, Rinne JO, Hietala J, Kaasinen V (2012a) Mesolimbic dopamine release is linked to symptom severity in pathological gambling. NeuroImage 60:1992–1999

    CAS  PubMed  Google Scholar 

  • Joutsa J, Martikainen K, Niemelä S, Johansson J, Forsback S, Rinne JO, Kaasinen V (2012b) Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord 27:778–782

    CAS  PubMed  Google Scholar 

  • Joutsa J, Martikainen K, Vahlberg T, Voon V, Kaasinen V (2012c) Impulse control disorders and depression in Finnish patients with Parkinson’s disease. Parkinsonism Relat Disord 18:155–160

    PubMed  Google Scholar 

  • Joutsa J, Rinne JO, Eskola O, Kaasinen V (2013) Reduced striatal dopamine synthesis capacity is associated with symptoms of depression in patients with de novo unmedicated Parkinson’s disease. J Parkinsons Dis 3:325–329

    CAS  PubMed  Google Scholar 

  • Kaasinen V, Någren K, Hietala J, Oikonen V, Vilkman H, Farde L, Halldin C, Rinne JO (2000) Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease. Neurology 54:1482–1487

    CAS  PubMed  Google Scholar 

  • Kaasinen V, Nurmi E, Bergman J, Eskola O, Solin O, Sonninen P, Rinne JO (2001) Personality traits and brain dopaminergic function in Parkinson’s disease. Proc Natl Acad Sci U S A 98:13272–13277

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kaasinen V, Aalto S, NAgren K, Hietala J, Sonninen P, Rinne JO (2003) Extrastriatal dopamine D(2) receptors in Parkinson’s disease: a longitudinal study. J Neural Transm 110:591–601

    CAS  PubMed  Google Scholar 

  • Kaasinen V, Aalto S, Någren K, Rinne JO (2004) Insular dopamine D2 receptors and novelty seeking personality in Parkinson’s disease. Mov Disord 19:1348–1351

    PubMed  Google Scholar 

  • Kiferle L, Ceravolo R, Giuntini M, Linsala G, Puccini G, Volterrani D, Bonuccelli U (2014) Caudate dopaminergic denervation and visual hallucinations: evidence from a 123I-FP-CIT SPECT study. Parkinsonism Relat Disord 20:761–765

    PubMed  Google Scholar 

  • Kim YD, Jeong HS, Song IU, Chung YA, Namgung E, Kim YD (2016) Brain perfusion alterations in depressed patients with Parkinson’s disease. Ann Nucl Med 30:731–737

    CAS  PubMed  Google Scholar 

  • Ko JH, Antonelli F, Monchi O, Ray N, Rusjan P, Houle S, Lang AE, Christopher L, Strafella AP (2013) Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson’s disease. Hum Brain Mapp 34:1591–1604

    PubMed  Google Scholar 

  • Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M (2007) Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson’s disease. Eur J Neurosci 25:3132–3136

    PubMed  Google Scholar 

  • Landis BN, Burkhard PR (2008) Phantosmias and Parkinson disease. Arch Neurol 65:1237–1239

    PubMed  Google Scholar 

  • Le Jeune F, Drapier D, Bourguignon A, Péron J, Mesbah H, Drapier S, Sauleau P, Haegelen C, Travers D, Garin E, Malbert CH, Millet B, Vérin M (2009) Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 73:1746–1751

    PubMed  Google Scholar 

  • Linnet J, Møller A, Peterson E, Gjedde A, Doudet D (2011) Dopamine release in ventral striatum during Iowa gambling task performance is associated with increased excitement levels in pathological gambling. Addiction 106:383–390

    PubMed  Google Scholar 

  • Martini A, Dai Lago D, Edelstyn NMJ, Salgarello M, Lugoboni F, Tamburin S (2018) Dopaminergic neurotransmission in patients with Parkinson’s disease and impulse control disorders: a systematic review and meta-analysis of PET and SPECT studies. Front Neurol 9:1018. https://doi.org/10.3389/fneur.2018.01018

    Article  PubMed  PubMed Central  Google Scholar 

  • Matsui H, Nishinaka K, Oda M, Hara N, Komatsu K, Kubori T, Udaka F (2006a) Hypoperfusion of the auditory and prefrontal cortices in Parkinsonian patients with verbal hallucinations. Mov Disord 21:2165–2169

    PubMed  Google Scholar 

  • Matsui H, Nishinaka K, Oda M, Hara N, Komatsu K, Kubori T, Udaka F (2006b) Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov Disord 21:2140–2144

    PubMed  Google Scholar 

  • Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F (2006c) Minor depression and brain perfusion images in Parkinson’s disease. Mov Disord 21:1169–1174

    PubMed  Google Scholar 

  • Matsui H, Nishinaka K, Miyoshi T, Hara N, Oda M, Kubori T, Udaka F (2007) Thalamic hyperperfusion in verbal hallucination of Parkinsonian patients. Intern Med 46:1765–1769

    PubMed  Google Scholar 

  • Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN, Robinson RG (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 28:57–64

    CAS  PubMed  Google Scholar 

  • Menza MA, Mark MH, Burn DJ, Brooks DJ (1995) Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 7:176–179

    CAS  PubMed  Google Scholar 

  • Nagano-Saito A, Washimi Y, Arahata Y, Iwai K, Kawatsu S, Ito K, Nakamura A, Abe Y, Yamada T, Kato T, Kachi T (2004) Visual hallucination in Parkinson’s disease with FDG PET. Mov Disord 19:801–806

    PubMed  Google Scholar 

  • Niccolini F, Politis M (2014) Dopamine receptor mapping with PET imaging in Parkinson’s disease. J Neurol 261:2251–2263

    CAS  PubMed  Google Scholar 

  • Nishio Y, Yokoi K, Hirayama K, Ishioka T, Hosokai Y, Gang M, Uchiyama M, Baba T, Suzuki K, Tadeka A, Mori E (2018) Defining visual illusions in Parkinson’s disease: Kinetopsia and object misidentification illusions. Parkinsonism Relat Disord 55:111. [Epub ahead of print]. https://doi.org/10.1016/j.parkreldis.2018.05.023

    Article  PubMed  Google Scholar 

  • O’Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, Djamshidian A, Lees AJ, Piccini P (2011) Cue-induced striatal dopamine release in Parkinson’s disease-associated impulsive-compulsive behaviours. Brain 134:969–978

    PubMed  Google Scholar 

  • Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H (2005) Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 65:1708–1715

    CAS  PubMed  Google Scholar 

  • Okada K, Suyama N, Oguro H, Yamaguchi S, Kobayashi S (1999) Medication-induced hallucination and cerebral blood flow in Parkinson’s disease. J Neurol 246:365–368

    CAS  PubMed  Google Scholar 

  • Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Sakamoto M (1999) Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson’s disease: a double-tracer positron emission tomography study. Ann Neurol 46:723–731

    CAS  PubMed  Google Scholar 

  • Pålhagen SE, Ekberg S, Wålinder J, Granérus AK, Granerus G (2009) HMPAO SPECT in Parkinson’s disease (PD) with major depression (MD) before and after antidepressant treatment. J Neurol 256:1510–1518

    PubMed  Google Scholar 

  • Pasquini J, Durcan R, Wiblin L, Gersel Stokholm M, Rochester L, Brooks DJ, Burn D, Pavese N (2019a) Clinical implications of early caudate dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 90:1098. [Epub ahead of print]. https://doi.org/10.1136/jnnp-2018-320157

    Article  PubMed  Google Scholar 

  • Pasquini J, Ceravolo R, Brooks DJ, Bonuccelli U, Pavese N (2019b) Progressive loss of raphe nuclei serotonin transporter in early Parkinson’s disease: a longitudinal 123I-FP-CIT SPECT study. Parkinsonism Relat Disord. [Epub ahead of print]. https://doi.org/10.1016/j.parkreldis.2019.03.025

  • Pizzagalli DA, Berretta S, Wooten D, Goer F, Pilobello KT, Kumar P, Murray L, Beltzer M, Boyer-Boiteuau A, Alpert N, El-Fakhri G, Mechawar N, Vitaliano G, Turecki G, Normandin M (2019) Assessment of striatal dopamine transporter binding in individuals with major depressive disorder: in vivo positron emission tomography and postmortem evidence. JAMA Psychiatry 76:854. [Epub ahead of print]. https://doi.org/10.1001/jamapsychiatry.2019.0801

    Article  PubMed  PubMed Central  Google Scholar 

  • Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P (2010a) Staging of serotonergic dysfunction in Parkinson’s disease: an in vivo 11C-DASB PET study. Neurobiol Dis 40:216–221

    CAS  PubMed  Google Scholar 

  • Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P (2010b) Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 75:1920–1927

    CAS  PubMed  Google Scholar 

  • Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Björklund A, Lindvall O, Piccini P (2012) Serotonin neuron loss and nonmotor symptoms continue in Parkinson’s patients treated with dopamine grafts. Sci Transl Med 4:128ra41

    PubMed  Google Scholar 

  • Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, Borghammar P, Brooks DJ, Pavese N (2015) Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain 138:2964–2973

    PubMed  Google Scholar 

  • Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, Antonelli F, Houle S, Lang AE, Strafella AP (2012) Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson’s patients with medication-induced pathological gambling: a [11C]FLB-457 and PET study. Neurobiol Dis 48:519–525

    CAS  PubMed  PubMed Central  Google Scholar 

  • Rektorova I, Srovnalova H, Kubikova R, Prasek J (2008) Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson’s disease. Mov Disord 23:1580–1587

    PubMed  Google Scholar 

  • Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314–1322

    PubMed  Google Scholar 

  • Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ (1994) Depression in Parkinson’s disease. A positron emission study. Br J Psychiatry 165:333–339

    CAS  PubMed  Google Scholar 

  • Rinne UK, Laihinen A, Rinne JO, Någren K, Bergman J, Ruotsalainen U (1990) Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson’s disease. Mov Disord 5:55–59

    CAS  PubMed  Google Scholar 

  • Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF, Ferrannini E, Tartaglione B, Defazio G, Rubini G, Livrea P (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord 24:2097–2103

    PubMed  Google Scholar 

  • Schmitt GJ, Frodl T, Dresel S, la Fougère C, Bottlender R, Koutsouleris N, Hahn K, Möller HJ, Meisenzahl EM (2006) Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 256:115–121

    CAS  PubMed  Google Scholar 

  • Schrag A (2006) Quality of life and depression in Parkinson’s disease. J Neurol Sci 248:151–157

    PubMed  Google Scholar 

  • Shinotoh H, Inoue O, Hirayama K, Aotsuka A, Asahina M, Suhara T, Yamazaki T, Tateno Y (1993) Dopamine D1 receptors in Parkinson’s disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 56:467–472

    CAS  PubMed  PubMed Central  Google Scholar 

  • Singh A, Kandimala G, Dewey RB, O’Suilleabhain P (2007) Risk factors for pathologic gambling and other compulsions among Parkinson’s disease patients taking dopamine agonists. J Clin Neurosci 14:1178–1181

    CAS  PubMed  Google Scholar 

  • Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Van Eimeren T, Rusjan P, Houle S, Strafella AP (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132:1376–1385

    CAS  PubMed  Google Scholar 

  • Strecker K, Wegner F, Hesse S, Becker GA, Patt M, Meyer PM, Lobsien D, Schwarz J, Sabri O (2011) Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter. J Neurol 258:19–26

    CAS  PubMed  Google Scholar 

  • Suhara T, Yasuno F, Sudo Y, Yamamoto M, Inoue M, Okubo Y, Suzuki K (2001) Dopamine D2 receptors in the insular cortex and the personality trait of novelty seeking. NeuroImage 13:891–895

    CAS  PubMed  Google Scholar 

  • Taylor AE, Saint-Cyr JA, Lang AE, Kenny FT (1986) Parkinson’s disease and depression. A critical re-evaluation. Brain 109(Pt 2):279–292

    PubMed  Google Scholar 

  • Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, LeBars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, Krack P (2010) Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain 133:1111–1127

    PubMed  Google Scholar 

  • Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, Nakamura H, Hattori N, Arai H (2011) Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuro-Psychopharmacol Biol Psychiatry 35:1704–1708

    Google Scholar 

  • Vilas D, Pont-Sunyer C, Tolosa E (2012) Impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S80–S84

    PubMed  Google Scholar 

  • Weintraub D, Stern MB (2005) Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 13:844–851

    PubMed  Google Scholar 

  • Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, Duda JE, Stern MB, Mozley D, Katz IR (2005) Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med 46:227–232

    CAS  PubMed  Google Scholar 

  • Weintraub D, Koester J, Potenza M, Siderowf A, Stacy M, Voon V, Whetteckey J, Wunderlich G, Lang A (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589–595

    PubMed  Google Scholar 

  • Yoritaka A, Ohizumi H, Tanaka S, Hattori N (2009) Parkinson’s disease with and without REM sleep behaviour disorder: are there any clinical differences? Eur Neurol 61:164–170

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Neurosciences and Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland

    Valtteri Kaasinen

Authors
  1. Valtteri Kaasinen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valtteri Kaasinen .

Editor information

Editors and Affiliations

  1. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Rudi A.J.O. Dierckx

  2. Faculty of Electrical Engineering, Medical Engineering and Computer Science, Offenburg University, Offenburg, Germany

    Andreas Otte

  3. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Erik F. J. de Vries

  4. Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands

    Aren van Waarde

  5. Biomedical Sciences of Cells and Systems, University Medical Center Groningen, Groningen, The Netherlands

    Iris E. Sommer

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaasinen, V. (2021). PET and SPECT in Psychiatric Complications of Parkinson’s Disease. In: Dierckx, R.A., Otte, A., de Vries, E.F.J., van Waarde, A., Sommer, I.E. (eds) PET and SPECT in Psychiatry. Springer, Cham. https://doi.org/10.1007/978-3-030-57231-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-57231-0_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-57230-3

  • Online ISBN: 978-3-030-57231-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation